×
FB Live: School's In (Again) -- Reopening Amid the Delta Surge
https://www.medpagetoday.com/infectiousdisease/covid19/94305

Aug 31st, 2021 - Topic: As schools around the U.S. reopen against the backdrop of the Delta variant -- which is causing spikes in hospitalization among kids -- teachers, school boards, and parents are faced with making major decisions about how best to keep children and staff safe. To make matters worse, the politics around back-to-school discussions have gotten messy. Guest: Tina Q. Tan, MD, professor of pedia...

CDC Staff Floats 'Risk-Based Approach' to Potential Booster Doses
https://www.medpagetoday.com/infectiousdisease/covid19vaccine/94293

Aug 30th, 2021 - A risk-based booster dose strategy for COVID-19 vaccines could target populations at risk of severe disease and those critical to the public health infrastructure, CDC staff said at a meeting of CDC's Advisory Committee on Immunization Practices (ACIP) on Monday. Though FDA has yet to review data on booster doses for COVID-19 vaccines among the general population, CDC staff presented a prelimin...

Past Infection May Better Protect Against Delta Than Vaccine, but …
https://www.medpagetoday.com/infectiousdisease/covid19/94258

Aug 28th, 2021 - A prior infection from COVID-19 was more protective than vaccine-induced immunity in reducing the risk of infection and symptomatic illness from the Delta variant, according to a retrospective observational study from Israel. Those who received both doses of the Pfizer/BioNTech vaccine in January or February of this year had a 13.06-fold increased risk (95% CI 8.08-21.11) of SARS-CoV-2 infectio...

'Pandemic of the Unvaccinated?' Not Really, Advocate Says
https://www.medpagetoday.com/infectiousdisease/covid19vaccine/94211

Aug 25th, 2021 - Is the current COVID-19 surge a "pandemic of the unvaccinated?" No, according to Rhea Boyd, MD, MPH, pediatrician and co-developer of the "The Conversation: Between Us, About Us" project to encourage more people of color to get vaccinated. "This is not a pandemic of the unvaccinated," Boyd said Wednesday at a virtual event sponsored by the Alliance for Health Policy. Instead, "what we really ex...

Tracking SARS-CoV-2 variants
https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
World Health Organization

May 31st, 2021 - All viruses, including SARS-CoV-2, the virus that causes COVID-19, change over time. Most changes have little to no impact on the virus’ properties. However, some changes may affect the virus’s properties, such as how easily it spreads, the associated disease severity, or the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures.

ESMO Virtual Congress 2020: Meeting
https://www.esmo.org/meetings/esmo-virtual-congress-2020

Sep 18th, 2020 - Bringing innovation to cancer patients. The ESMO Virtual Congress 2020 will present promising new developments aimed at improving cancer patient care. In response to the needs of the moment, the scientific programme will include a dedicated COVID-19 and cancer research track. Take part in Europe's most prestigious platform for oncology stakeholders.

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2768602
JAMA Internal Medicine;

Jul 15th, 2020 - Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection began in December 2019 in Wuhan, China, more than 6 million people have developed coronavirus disease 2019 (COVID-19), and more than 350 000 have died.1 Critical illness from COVID-19 in China, Italy, and other countries has strained intensive care unit (ICU) resources and produced a wide spectrum of sh...

COVID-19 in Immunocompromised Hosts: What We Know So Far
https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa863/5864040
Clinical Infectious Diseases; Monica Fung MD, MPH et. al.

Jun 27th, 2020 - The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features and outcomes of COVID-19 among immunosuppressed patients, who are at presumed risk for more severe disease but who may also have decreased detrimental inflammatory responses, are no...

Progressing malignancy linked to higher mortality among patients with cancer and COVID-19
https://www.healio.com/hematology-oncology/practice-management/news/online/{a24c9adf-558c-4ccb-ba95-8c5a2168dcbe}/progressing-malignancy-linked-to-higher-mortality-among-patients-with-cancer-and-covid-19

May 31st, 2020 - Progressing cancer appeared independently associated with increased risk for death among a cohort of patients with malignancies and COVID-19, according to study results presented during the ASCO20 Virtual Scientific Program.

Merry-Jennifer Markham, MD: Perspectives on Three Abstracts From the ASCO Cancer Communications Chair
https://ascopost.com/videos/asco20-virtual-scientific-program/merry-jennifer-markham-perspectives-on-three-abstracts/

May 30th, 2020 - Merry-Jennifer Markham, MD, ASCO’s Cancer Communications Chair, gives her views on key papers presented at the ASCO20 Virtual Scientific Program, addressing gynecologic malignancies and COVID-19.

Widespread Impact of COVID-19 on Cancer Research and Treatment
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200211/full/

May 30th, 2020 - There is no doubt that the COVID-19 pandemic has negatively affected cancer research and patient treatment worldwide. ASCO addressed this during the ASCO20 Virtual Scientific Program during the session, “Cancer Care in the Time of COVID: Assessing Impact and Future Directions.” The session began with an overview given by Norman E. Sharpless, MD, director of the National Cancer Institute (NCI). ...

NCI director: COVID-19 having ‘profound’ effects on cancer outcomes, research
https://www.healio.com/hematology-oncology/practice-management/news/online/{56279316-24e1-4c34-8527-2538a95b52a9}/nci-director-covid-19-having-profound-effects-on-cancer-outcomes-research

May 30th, 2020 - The oncology community has demonstrated a remarkable ability to adapt amid the COVID-19 pandemic but must be prepared for its long-term effects on cancer care, NCI Director Norman E. “Ned” Sharpless, MD, told ASCO Virtual Scientific Program attendees.

Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization
https://ascopost.com/news/may-2020/study-finds-patients-with-lung-cancer-infected-with-covid-19-recently-treated-with-chemotherapy-at-higher-risk-of-death/

May 29th, 2020 - Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was the use of steroids or anticoagulants. Prior administration of immunotherapy and chemoimmunotherapy ...

Patients With Cancer—Especially Progressive Disease—Infected With COVID-19 May Have an Increased Risk of Death
https://ascopost.com/news/may-2020/patients-with-cancer-especially-progressive-disease-infected-with-covid-19-may-have-an-increased-risk-of-death/

May 29th, 2020 - A large cohort study by the COVID-19 and Cancer Consortium evaluating the impact of COVID-19 on patients with cancer has found that all-cause 30-day mortality and severe illness were significantly higher in this population than previously reported in the general population. Mortality and severe illness were associated with general risk factors, as well as those unique to patients with cancer, a...

Prior chemotherapy linked to mortality risk among patients with thoracic cancers, COVID-19
https://www.healio.com/hematology-oncology/lung-cancer/news/online/{57d3d009-7215-423e-a152-9ff210a6afaa}/prior-chemotherapy-linked-to-mortality-risk-among-patients-with-thoracic-cancers-covid-19

May 29th, 2020 - Prior use of chemotherapy appeared associated with an increased risk for death among patients with lung or other thoracic cancers and COVID-19, according to study results presented during the ASCO20 Virtual Scientific Program.

Active cancer increases death risk in patients with COVID-19
https://www.mdedge.com/hematology-oncology/article/222977/patient-survivor-care/active-cancer-increases-death-risk-patients

May 28th, 2020 - Patients with COVID-19 and progressing cancer had a fivefold increase in the risk of 30-day mortality, compared with COVID-19–positive cancer patients who were in remission or had no evidence of cancer, according to data from the COVID-19 and Cancer Consortium (CCC19) registry.

Active Cancer Strongly Associated With Increased COVID-19 Mortality
https://www.onclive.com/conference-coverage/asco-2020/active-cancer-strongly-associated-with-increased-covid19-mortality

May 28th, 2020 - An analysis of data collected in the COVID-19 and Cancer Consortium (CCC19) registry showed that patients with progressive cancer were 5.2-times more likely to die within 30 days of being diagnosed with novel coronavirus 19 (COVID-19) compared with patients in remission or with no evidence of disease.

Recent Chemotherapy Raises COVID-19-Related Mortality Risk for Patients With Thoracic Cancer
https://www.onclive.com/conference-coverage/asco-2020/recent-chemotherapy-raises-covid19related-mortality-risk-for-patients-with-thoracic-cancer

May 28th, 2020 - Chemotherapy administered within 3 months of a diagnosis of coronavirus disease 2019 (COVID-19) increased the risk of death in patients with thoracic cancer, according to findings from the global TERAVOLT Consortium registry.

COVID-19-Related Mortality Risk Increases With Recent Chemotherapy in Thoracic Cancer
https://www.targetedonc.com/view/covid-19-related-mortality-risk-increases-with-recent-chemotherapy-in-thoracic-cancer

May 28th, 2020 - The risk of death in patients with thoracic cancer was inflated with the administration of chemotherapy within 3 months of a coronavirus disease 2019 (COVID-19) diagnosis, findings from the global TERAVOLT Consortium registry show.

COVID-19 Mortality Shows Strong Correlation With Active Cancer
https://www.targetedonc.com/view/covid-19-mortality-shows-strong-correlation-with-active-cancer

May 28th, 2020 - Death in patients with progressive cancer within 30 days of the coronavirus disease 2019 (COVID-19) diagnosis was 5.2 times compared with patients in remission or with no evidence of disease, data from the COVID-19 and Cancer Consortium (CCC19) registry shows.